Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067236 · ClinicalTrials.gov registry record · Phase 2
Study of Oral PG-116800 Following a Heart Attack
A Phase 2 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 2
- Development phase
- 253
- Enrollment target
NCT00067236 is a Phase 2 study that has completed, run by Procter and Gamble. The registered enrollment target is 253 participants.
The verdict
NCT00067236, a Phase 2 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 253 participants
- Enrollment target
Study Summary
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.
Interventions
- DRUG Placebo tablet
- DRUG PG-116800 (given as PG-530742)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067236
The ClinicalTrials.gov registry entry for NCT00067236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Procter and Gamble, which has 70 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT00067236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067236 about?
NCT00067236 is a clinical study titled "Study of Oral PG-116800 Following a Heart Attack". The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.
What is the current status of trial NCT00067236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 253 participants. The study started on 2003-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00067236?
The interventions under investigation include: Placebo tablet (DRUG), PG-116800 (given as PG-530742) (DRUG).
Who is sponsoring clinical trial NCT00067236?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.